Linked Life Data

19468284

Source:http://linkedlifedata.com/resource/pubmed/id/19468284

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2009-11-10
pubmed:abstractText
Pharmacologic therapies are currently being evaluated for the prevention of prostate cancer (PCa). As additional clinical data become available regarding their benefits and risks, an examination of their economic impact will also be important. The purpose of this study was to estimate mean per patient PCa-related costs during the first year following diagnosis and to examine the extent to which initial therapies are used, by initial cancer stage. Our data show that health-care costs were significant and varied by stage. With average first-year PCa-related costs of US$13,091, prevention strategies have the potential to reduce health-care costs.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:issn
1476-5608
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
12
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
355-60
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
First-year costs of treating prostate cancer: estimates from SEER-Medicare data.
pubmed:affiliation
Department of Urology, UT Southwestern Medical Center at Dallas, Dallas, TX, USA.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't